Roche Agreement

A full list of the products contained will be available on the following websites: www.lifescience.roche.com/distributionagreement or www.sigma-aldrich.com/roche. Please sign up for up-to-date information as soon as it becomes available. Roche`s powerful combination of high-quality products and Sigma Aldrich service excellence creates a powerful promise of value for these products as part of life sciences research. As part of the agreement, Sigma-Aldrich will use its distribution, marketing and e-commerce expertise and use the strength of its relationships with the scientific community to present and distribute Roche`s proteomics, cellular analysis and conventional PCR reagents and kits. «Thanks to our pioneering work in RNA biology, we have established a platform for the development and adaptation of drug search tools that allow us to predict and validate the structure of RNA targets, locate drug pockets, identify staggering results, and implement medical chemistry programs to discover a new class of RNA-targeted drugs optimized for impotence, selectivity and safety. This agreement with Roche underscores the value of our rSM platform and will allow us to continue to make leading discoveries and other scientific contributions in this area,» said Jennifer C. Petter, Ph.D., Founder and Chief Scientific Officer of Arrakis. Markus Gemuend, Head of Sub-Saharan Africa, said: «It is essential that we work together to improve outcomes for people with breast cancer and hepatitis in Ghana who do not have access to care. This comprehensive agreement reflects a multidisciplinary approach to improving care and ensuring the earlier diagnosis and treatment we so desperately need.

In this focused research cooperation alone, Lead Pharma and Roche will collaborate on research activities until a preclinical candidate is selected, according to which Roche will be responsible for global development and commercialization. Under the agreement, Lead Pharma receives a down payment of 10 million euros and can receive research funds and payments for preclinical steps; Total potential payments, including research, development, regulation and distribution, can amount to a total of 260 million euros, plus royalties for global sales.